Navigation Links
A ray of hope in Angioplasty dilemma

A new technique to keeping heart arteries flowing easily after angioplasty shows fantastic success in early testing, visibly solving a major weakness of the common procedure.Doctors released the longest follow up with the new technique - the drug-coated stent. In testing on 30 patients over three years, they found it to be 100 percent effective, an accomplishment almost unheard of in medicine.//

More than 1 million Americans undergo angioplasty annually, and the new approach is likely to be used on most of them if these promising early results hold up in further testing. They could be on the market as early as next year.// During angioplasty, doctors fish tiny balloons through clogged heart arteries, then inflate them briefly to open up blood flow. Frequently, though, the arteries squeeze shut again. In recent years, doctors have often left behind tiny wire coils, called stents, to prop the arteries open.

However, about one-quarter of the time, the reopened artery closes off, a condition called restenosis. It usually occurs when fast-growth scar-like tissue fills the artery, and it must be fixed with a repeat angioplasty or a coronary bypass.

The solution to this dilemma appears to be a new kind of stent that is coated with medicines that gradually ooze into the artery. The drugs keep cells from growing. At least eight different varieties - coated with different growth-inhibiting medicines - are now in testing, and many more are under development. The first was Cordis Corp.'s stent coated with the immune suppressing drug rapamycin, tested on patients in Brazil and the Netherlands.

Dr. J. Eduardo Sousa of the Dante Pazzanese Institute of Cardiology in Sao Paulo presented two years of follow up with those 30 initial patients. While three of them have needed heart procedures for worsening disease in other parts of their hearts, all of the areas treated with the Cordis stents are flowing freely. Sousa projected an X-ray of o ne of the patient's hearts, showing a wide, obstruction-free artery. ``No lesion. No problem,'' he said. ``The artery is completely open after two years follow up.''

Dr. Jean Fajadet of Thoraxcenter in Rotterdam gave results with the same stent after seven months in 238 patients. Again, not a single stent clogged up, compared with restenosis in 26 percent of those getting ordinary stents.

Dr. Sidney Smith, chief medical officer of the American Heart Association, cautioned that large, careful studies must be finished comparing the new stents with the ordinary kind. Nevertheless, he said, ``these are very impressive and very encouraging results. When you see zero restenosis at one year, it's a breakthrough. It's almost too good to believe when you see zero.''

Especially encouraging, Smith said, is the fact they seem to work in unusually small arteries and in those of diabetic patients. Both are very prone to reclogging. Dr. Greg Stone of Lenox Hill Hospital in New York City said the first of these stents could be available in 2003. Results of at least three large studies, necessary to win Food and Drug Administration approval, are expected on rival products within the next year.


'"/>




Related medicine news :

1. Cholesterol Drug Helps After Angioplasty
2. Angioplasty Should be the Standard
3. The Success Rate Of Angioplasty In Female Patients Low
4. Angioplasty The Much Preferred Treatment Of Choice For Heart Attacks
5. Angioplasty death risk reduced by doubling drug dose
6. Angioplasty death risk reduced by doubling drug dose
7. Angioplasty plus stenting better than thrombolysis for elderly patients with AMI
8. Patients Fare Better With Doctors Who Do More Angioplasty Procedures
9. Researchers Begin Study To Find Out If Angioplasty Can Be Safely Done In Smaller Hospitals
10. Drug-Coated Stents Work Better In Diabetic Patients After Angioplasty
11. Togadiyas Condition Stable After Undergoing Angioplasty
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2017)... ... June 27, 2017 , ... From June 20-22, EarQ and ... in Syracuse, New York, where EarQ is headquartered. , Together, the organizations educate ... with today’s savvy consumer, and the latest in hearing technology. At the event, ...
(Date:6/27/2017)... ... June 27, 2017 , ... Atmosera , ... Atmosera Managed Azure Services . The trusted, transparent, and secure solution for the ... growing customer base. Atmosera’s next generation services include integrated capabilities for public, private, ...
(Date:6/27/2017)... ... June 27, 2017 , ... A+ Orthodontics is ... specialty that focuses on treating alignment and occlusion irregularities. Treatment often includes the ... , North Hollywood dentist , Dr. Garemani, along with Dr. Reza and ...
(Date:6/26/2017)... ... June 26, 2017 , ... Dr. Martin Bastuba, MD, FACS, ... with the Fertility Center of California, is pleased to announce the addition of ... and TESA (percutaneous testicular sperm extraction). These minimally invasive treatments are primarily used ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... ... coding staff, and consumers are seeing lots of red these days. According to ... inaccurate charges that result from medical coding errors(1). Some studies point to Electronic ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... GAITHERSBURG, Md. , June 7, 2017  Novavax, Inc., ... the second of two Phase 2 trials of its RSV ... women of child bearing age have been published in the ... this publication have been shared in prior scientific conferences). The ... trial in April 2014. Novavax is developing the RSV F ...
(Date:6/2/2017)... 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical ... new findings demonstrating positive biochemical outcomes related to more ... The data will be presented at the ERA-EDTA Congress ... Spain . The research was ... Network in Europe (KIHDNEy) ...
(Date:5/29/2017)... AVIV, Israel, May 29, 2017  Cellect Biotechnology Ltd. ... innovative technology which enables the functional selection of stem ... results for the first quarter ended March 31 st ... with our accomplishments in the first quarter of 2017," ... first quarter, we announced the treatment of the first ...
Breaking Medicine Technology: